James Brown, MD
Internal Medicine · Spartanburg, SCNPI 1134190077
Payments from drug & device makers
Across 304 payments — averaging $15.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$696
- Amarin Pharma, Inc.$545
- Novartis$400
- Pfizer$380
- AstraZeneca$333
- AbbVie$208
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,59299%
- Education$120%
- Entertainment$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 52 | $696 |
| Amarin Pharma, Inc. | 38 | $545 |
| Novartis | 22 | $400 |
| Pfizer | 31 | $380 |
| AstraZeneca | 20 | $333 |
| AbbVie | 16 | $208 |
| Astellas Pharma US Inc | 10 | $184 |
| Novo Nordisk | 12 | $179 |
| Boehringer Ingelheim | 12 | $169 |
| Lilly USA, LLC | 10 | $156 |
| Sunovion Pharmaceuticals Inc. | 8 | $123 |
| Kowa Pharmaceuticals America, Inc. | 9 | $113 |
| Medtronic | 4 | $110 |
| Esperion Therapeutics, Inc. | 5 | $92 |
| Sanofi-aventis U.S. LLC | 5 | $82 |
| Otsuka America Pharmaceutical, Inc. | 3 | $81 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $73 |
| Radius Health, Inc. | 3 | $68 |
| Exact Sciences | 4 | $62 |
| Abbott | 3 | $61 |
| Phathom Pharmaceuticals, Inc. | 3 | $57 |
| Inari Medical, Inc. | 2 | $55 |
| GSK | 4 | $53 |
| Hitachi Healthcare Americas Corp. | 1 | $47 |
| Dynavax Technologies Corporation | 3 | $45 |
| Arbor Pharmaceuticals, Inc. | 3 | $44 |
| Aimmune Therapeutics, Inc. | 2 | $30 |
| Merck | 2 | $28 |
| Johnson & Johnson | 2 | $23 |
| Insmed, Inc. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $19 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Dexcom, Inc. | 1 | $14 |
| IBSA Pharma Inc. | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Eisai Inc. | 1 | $11 |
How this compares
$4,651 in reported general payments places this provider in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 124 | $140,682 |
| JardianceEmpagliflozin | 114 | $137,496 |
| OzempicSemaglutide | 109 | $104,605 |
| JanumetSitagliptin Phos/Metformin Hcl | 40 | $59,529 |
| Repatha SureclickEvolocumab | 45 | $50,058 |
| XareltoRivaroxaban | 33 | $38,850 |
| FarxigaDapagliflozin Propanediol | 32 | $32,543 |
| WegovySemaglutide | 16 | $21,005 |
| NexletolBempedoic Acid | 21 | $14,664 |
| MyrbetriqMirabegron | 20 | $13,748 |
| MounjaroTirzepatide | 12 | $10,132 |
| Rosuvastatin Calcium | 435 | $9,253 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $7,541 |
| Atorvastatin Calcium | 759 | $6,742 |
| LantusInsulin Glargine,hum.Rec.Anlog | 16 | $4,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $380 | $140,682124 claims |
| Boehringer IngelheimJardiance | $169 | $137,496114 claims |
| Novo NordiskOzempic, Wegovy | $179 | $125,611125 claims |
| MerckJanumet | $28 | $59,52940 claims |
| Johnson & JohnsonXarelto | $23 | $38,85033 claims |
| AstraZenecaFarxiga | $333 | $32,54332 claims |
| Esperion Therapeutics, Inc.Nexletol | $92 | $14,66421 claims |
| Astellas Pharma US IncMyrbetriq | $184 | $13,74820 claims |
| Lilly USA, LLCMounjaro | $156 | $10,13212 claims |
| Sanofi-aventis U.S. LLCLantus | $82 | $4,89116 claims |
| AbbVieSynthroid | $208 | $1,89135 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,498 internal medicine providers in South Carolina.
Other internal medicine in Spartanburg
- Suzanne KovacsSpartanburg$14K
- Rica SantiagoMt Pleasant$10.7M
- Richard MillsMt Pleasant$5.5M
- Yvonne DavisMount Pleasant$2.4M
- David BolsterSummerville$2.3M
- Colby GrossmanSummerville$1.4M
- Amit ShahIndian Land$1.4M
- Philip NicolMurrells Inlet$782K
- Carl SofleyAnderson$673K
- Carl MitchellColumbia$564K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.